Eisai, Inc. has broken ground for a production and formulation R&D facility for parenteral oncology treatments in Research Triangle Park (RTP), NC. Eisai has a number of drugs in development for patients with cancer and recently entered the market through the acquisition of four oncology-related products from Ligand Pharmaceuticals. Eisai will invest $90 million in the 65,000-sq.-ft. facility, which will have aseptic processing suites, labs and other support functions. A separate $15 mi...